Amgen Inc. stock price, AMGN

Amgen Inc. stock chart:

Amgen Inc. close price: 160.41

Stock price forecast:

DOWN TO -1.24%
Target: 158.42

Total forecasts: 81
Reached: 17 (20.99%)

Total Win: 118.32 (67.17%)

DaysForecastsReached%Reached points%InvestedUnreached%Total%

Showing 1-10 of 531 items.
Date of ForecastStock PriceTarget PriceForecast Reached Date

Amgen Inc. latest news:

  • 04/06/2017 14:31:52

    BRIEF-Amgen says CEO Robert Bradway's total compensation for 2016 was $16.9 mln vs $16.1 mln in 2015 - SEC filing

    * Amgen Inc - CEO Robert Bradway's total compensation for 2016 was $16.9 million versus $16.1 million in 2015 - SEC filing Source text: ( Further company coverage:

  • 03/17/2017 14:31:25

    Wall St. flat as banks, Amgen weigh; Adobe rallies

    NEW YORK (Reuters) - U.S. stocks dipped on Friday as bank shares fell alongside Treasury yields while Adobe helped buoy the S&P tech sector and the Nasdaq Composite.

  • 03/17/2017 08:05:32

    Wall Street little changed as healthcare stocks weigh

    (Reuters) - U.S. stocks were little changed on Friday as a slide in Amgen dragged down the healthcare sector, offsetting gains in technology shares.

  • 03/12/2017 23:00:00

    Data on heart benefits of Amgen drug is key to unlocking sales

    March 13 (Reuters) - Data that should help unlock the sales potential of a potent new cholesterol medicine will be unveiled at the American College of Cardiology meeting this week as the future of the only rival drug rests with the courts in an ongoing patent dispute.

  • 03/06/2017 06:41:21

    Advaxis stock jumps 10% after FDA okays clinical trials for Amgen-partnered cancer drug

    Advaxis Inc. shares surged 10.6% in pre-market trade Monday after the company said the Food and Drug Administration would allow its ADXS-NEO, a cancer immunotherapy drug partnership with Amgen , to proceed to clinical trials. ADXS-NEO's approach targets neoantigens, which are seen as a promising avenue of cancer drug development, and the drug is only the second of this type with an Investigational New Drug application accepted by the FDA, according to a company spokesperson. Advaxis said it plans to start a phase 1 trial for the drug in multiple tumor types later this year. Amgen shares slumped 0.2% in pre-market trade Monday. Shares of Advaxis have risen 3.5% over the last three months, and shares of Amgen have surged 24.2% over the last three months, compared with a 7.7% rise in the S&P 500 . Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit for more information on this news.

  • 02/14/2017 14:47:05

    George Soros picks up Goldman Sachs, dumps Nvidia

    George Soros's hedge fund Soros Fund Management made a lot of changes to his portfolio in the fourth quarter, dumping positions in many companies and initiating positions in Goldman Sachs Group Inc. and Pandora Media Inc. . Soros decreased positions in Abbott Labs , Inc. , eBay Inc. , Netflix Inc. , and VMware Inc. . Soros also dumped positions in Activision Blizzard Inc. , Amgen Inc. , Barrick Gold Corp. , Coca-Cola Co. and Nvidia Corp. .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit for more information on this news.

  • 02/08/2017 14:49:37

    Federal appeals court decision will keep Regeneron/Sanofi drug at center of patent dispute on market, for now

    A federal appeals court temporarily stopped another judge's decision that would have forced Regeneron and Sanofi (SNY) to stop selling cholesterol drug Praluent. The Tuesday decision, though expected, "means that Praluent will not come off the market by Feb. 21," and could even stay on the market through the rest of the year, said Evercore ISI analyst Mark Schoenebaum. The previous judge's decision in favor of Amgen Inc. (AMGN) was a for Amgen (AMGN), and sent its shares up on Jan. 7, the day the decision...

  • 02/02/2017 16:21:54

    BRIEF-Amgen CEO expects to see U.S. tax reform

    * Amgen CEO says international expansion important element of long-term growth

  • 02/02/2017 15:03:49

    Amgen fourth quarter profit tops Street view, but 2017 outlook light

    (Reuters) - Amgen Inc on Thursday posted a higher-than-expected fourth-quarter profit, helped by a jump in sales of its Enbrel rheumatoid arthritis drug, but it issued a 2017 sales and earnings forecast range below current Wall Street estimates.

  • More trends:

    Amicus Therapeutics, Inc.FOLD | Amkor Technology, Inc.AMKR | Amphastar Pharmaceuticals, Inc.AMPH | Amsurg Corp.AMSG | Amsurg Corp.AMSGP | Amtech Systems, Inc.ASYS | AmTrust Financial Services, Inc.AFSI+18.43% | Amyris, Inc.AMRS | Anacor Pharmaceuticals, Inc.ANAC | ANADIGICS, Inc.ANAD |